靶向NY-ESO-1的TCR转导T细胞治疗恶性脑膜瘤的免疫治疗研究
本研究探讨靶向NY-ESO-1的TCR转导T细胞(TCR-T)对恶性脑膜瘤的疗效。体外实验显示TCR-T对高表达NY-ESO-1的脑膜瘤细胞有显著细胞溶解作用,且疗效与表达水平相关;体内实验表明系统性过继细胞转移可显著延长荷瘤小鼠生存期。提示靶向NY-ESO-1可能是治疗高级别脑膜瘤的可行免疫策略。
要点
- NY-ESO-1表达与脑膜瘤分级相关,高核表达预示更差的无进展生存期。
- 靶向NY-ESO-1的TCR-T在体外可诱导脑膜瘤细胞溶解,疗效与NY-ESO-1表达水平相关。
- 系统性过继转移TCR-T可显著延长高级别脑膜瘤颅内异种移植小鼠的中位总生存期。
核心结论
- 靶向NY-ESO-1的TCR-T可在体外诱导脑膜瘤细胞溶解,且疗效与NY-ESO-1表达相关。
- 系统性过继细胞转移可显著延长高级别脑膜瘤小鼠的生存期,提示靶向NY-ESO-1可能是临床可行的辅助免疫治疗策略。
研究设计与样本
- 对I-III级脑膜瘤标本进行免疫组化检测NY-ESO-1表达(n=35)。
- 建立原代脑膜瘤培养LB3750(I级)和永生化培养SF1335(I级)、CH157-HLA-A2.1(III级)。
- 将HLA-A2.1限制性NY-ESO-1 TCR-T细胞与脑膜瘤细胞共培养,评估体外实时肿瘤杀伤。
- 在免疫缺陷NSG小鼠颅内植入CH157-HLA-A2.1和SF1335细胞,进行系统性过继细胞转移(ACT)治疗,评估总生存期。
主要发现
- NY-ESO-1表达与肿瘤分级相关(n=35;p<0.01)。
- 高NY-ESO-1核表达预示更差的无进展生存期(p=0.0167)。
- CH157-HLA-A2.1细胞(天然高表达NY-ESO-1)与TCR-T共培养10小时和24小时后,分别经历>60%和近100%的细胞溶解,对照T细胞组相比p<0.0001。
- SF1335和LB3750细胞(低表达NY-ESO-1)与TCR-T共培养24小时后经历20%细胞溶解,对照相比p<0.0001。
- 系统性ACT of TCR-T使颅内CH157-HLA-A2.1异种移植NSG小鼠的中位总生存期显著增加49%(p<0.001)。
临床怎么用
- 靶向NY-ESO-1的TCR-T可能作为高级别脑膜瘤的辅助免疫治疗策略,尤其适用于NY-ESO-1高表达患者。
- 治疗前需评估肿瘤NY-ESO-1表达水平和HLA-A2.1限制性。
局限性
- 研究仅涉及体外细胞系和动物模型,尚未在人体中验证。
- 样本量有限(免疫组化n=35),需更大规模研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Malignant meningiomas lack effective immunotherapeutic options. NY-ESO-1 is a potential immunotherapeutic target, because it is the most frequently expressed cancer-testis-antigen in meningiomas. We investigated the efficacy of T-Cell-Receptor-Transduced T-Cells (TCR-T) targeting NY-ESO-1 in vitro and in vivo in meningiomas. METHODS: Immunohistochemistry was performed on Grade I-III meningioma specimens. Primary meningioma culture LB3750(Grade I) and immortalized cultures SF1335(Grade I) and CH157-HLA-A2.1(Grade III) were established and maintained in vitro. NY-ESO-1 TCR-T (HLA-A2.1 restricted) cells were co-cultured with primary and immortalized meningioma cells and assessed for real-time tumor killing in vitro. Immunodeficient NSG mice were intracranially implanted with CH157-HLA-A2.1 and SF1335 cells, treated with systemic adoptive cell transfer (ACT) of TCR-T, and assessed for overall survival in vivo. RESULTS: NY-ESO-1 expression correlated with tumor grade (n = 35; p < 0.01). High NY-ESO-1 nuclear expression predicted a worse progression-free-survival (p = 0.0167). CH157-HLA-A2.1 cells, with native high NY-ESO-1 expression, experienced > 60% and then nearly 100% cytolysis after co-culture with TCR-T for 10 and 24 h, respectively, compared with control T-cells (p < 0.0001). SF1335 and LB3750 cells, with low NY-ESO-1 expression, experienced 20% cytolysis after 24 h of co-culture with TCR-T compared to the control (p < 0.0001). Systemic ACT of TCR-T significantly increased the median overall survival in NSG mice bearing intracranial xenografts of CH157-HLA-A2.1 by 49% (p < 0.001). CONCLUSIONS: NY-ESO-1 TCR-T induces cytolysis in meningiomas in vitro, and its efficacy correlates with NY-ESO-1 expression. Systemic ACT results in significantly increased survival in vivo in high-grade meningioma. Therefore, targeting NY-ESO-1 may be a clinically feasible immunotherapeutic strategy for treating high-grade meningiomas. No effective immunotherapy exists for malignant meningioma. NY-ESO-1 is widely expressed in meningiomas but not in normal cells, making it an ideal immunotherapeutic target. Engineered T cells have been used to target NY-ESO-1 in melanomas and sarcomas but not in brain tumors. We found that T cells targeting NY-ESO-1 effectively killed meningiomas in vitro, with the efficacy correlating with tumor NY-ESO-1 expression. Adoptive cell transfer of these T cells results in significantly increased survival in vivo in high-grade meningiomas. Our study demonstrated that targeting NY-ESO-1 with T cells may be a clinically feasible adjuvant immunotherapeutic strategy for treating high-grade meningiomas.
引用
- Sun MZ, Contreras E, Treger J, et al. Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells. J Neurooncol. 2025. PMID: 40802116. doi:10.1007/s11060-025-05200-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。